U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-KSB



(Mark One)
[ X ]

Annual Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934

For the fiscal year ended December 31, 2003

[    ]

Transition Report Under Section 13 Or 15(D) Of The Securities Exchange Act Of 1934

For the transition period from _____ to _____

COMMISSION FILE NUMBER 000-49833



ACRONGENOMICS, INC.

(Name of small business issuer in its charter)





|NEVADA                                                         |  | 52-2219285                          
|-------------------------------------------------------------- |  | ------------------------------------
|(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
|                                                               |  |                                     
|                                                               |  |                                     
|                                                               |  |                                     
|(Address of principal executive offices)                       |  | (Zip Code)                          
|                                                               |  |                                     
|                                                               |  |                                     
|Issuer's telephone number                                      |  |                                     
|                                                               |  |                                     

Securities registered under Section 12(b) of the Exchange Act:  NONE.





Securities registered under Section 12(g) of the Exchange Act:



COMMON STOCK, PAR VALUE $0.001 PER SHARE.





Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.       Yes  [ X ]   No  [   ]



Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B is not contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. [  ]



State issuer's revenues for its most recent fiscal year  $1,078

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or the average bid and asked price of such common equity, as of a specified date within the past 60 days. (See definition of affiliate in Rule12b2Rule 12b-2 of the Exchange Act.) $12,276,000, based on the last sales price of our common stock of $2.40 per share on April 8, 2004.

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date.:  10,115,000 shares of Common Stock.













PART I



ITEM 1.

DESCRIPTION OF BUSINESS.

Our Corporate Organization



We were incorporated on August 17, 1999 under the laws of the State of Nevada. On February 25, 2004, we change the name of our corporation to Acrongenomics, Inc.  Our sole promoter from the date of incorporation to February 2, 2004, was Mr. Jack Morgan, our president, secretary and treasurer and our sole director during such time.  On February 2, 2004, Mr. W. Scott Lawler became our president, secretary and sole director.



We reported net losses of $21,576 and $24,818 for the two fiscal years ended December 2003 and 2002 respectively.  We have yet to earn any revenues. We will need additional working capital to be successful in our planned business activity and to complete our plan of operations for the coming year.  Our continuation as a going concern is dependent upon obtaining the additional working capital necessary to accomplish our objectives.  Accordingly, there is substantial doubt as to our ability to continue as a going concern.  Our auditors have made reference to the substantial doubt about our ability to continue as a going concern in their audit report on our audited financial statements for the year ended December 31, 2003.



Our Business Development Plan



Acrongenomics Inc.s corporate mandate is for the investigation and acquisition of companies in the pharmaceutical and biotechnology fields.  This change in February of 2004, in managements view, will better enhance shareholder value over the near and long term.



The target companies must have products that are at or near the market as well as research capabilities for the development of new products going forward.



The Company, with its new products, will enter into to strategic alliances with established pharmaceutical companies and distribution networks in order to maximize market penetration worldwide.



Early in 2004 the Company announced that it is in discussions with two companies with a view to their acquisition and to date have not finalized the terms of either deal.  These first two targeted companies were uncovered in Greece through an associate of the Company.  Both targets are situated in Athens where through its universities and colleges have a large untapped research and development program. The Company entered into a letter of intent to acquire a Greek patent. This proposed acquisition is subject to the Companys completion of its due diligence investigation of the patent and execution of a definitive patent acquisition agreement. The due diligence has not yet been completed and the definitive acquisition agreement has not been prepared.



The Company, through its expanding network will continue to look at all opportunities worldwide that fit within its mandate.



Although the Company is entering a highly competitive field, with many competitors that may be better financed for mergers and acquisitions, it believes that with the targeted companies that it is seeking, they can obtain a competitive advantage through control and adaptability.



The Company will only entertain acquisitions that have proprietary, patented or licensed products that will allow sufficient exclusive marketing in order to obtain market share for all its products.  Some or all of the products may require government approvals; therefore the company intends to have a strong liaison committee between the company and the government regulators.

1









It is the intentions of the Company to acquire target companies with shares of the Company and will only pursue such target companies that will value add to the overall operation of the Company.



The Company has expended no funds to date on any intended target except for due diligence costs associated with the investigation of said target companies.



The Company will hold all government regulations to the highest standards.



The Company expects to initially have 3-5 employees in its early stages and future employees will depend on the acquisitions completed.



Our Plan To Generate Revenues



It is too early in our development to be able to give a plan for generating revenues. As stated above, our plan is to seek and locate merger and acquisition candidates from whom we can build a solid pharmaceutical and biotechnology business. As we more fully develop and implement this plan, we will be able to commence development of a plan for generating revenues. The Company's ability to continue operations is contingent upon its ability to identify a prospective target business.



ITEM 2.

DESCRIPTION OF PROPERTY.

We have no properties and at this time have no agreements to acquire any properties.



We operate from our offices at 1530 9th Ave., S.E., Calgary, Canada. W. Scott Lawler, our sole officer and director, provides space to us on a rent-free basis and it is anticipated that this arrangement will remain until we successfully consummate a merger or acquisition. Management believes that this space will meet our needs for the foreseeable future.



ITEM 3.

LEGAL PROCEEDINGS.

We are not currently a party to any legal proceedings.



ITEM 4.

SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.



No matters were submitted to our security holders for a vote during the fourth quarter of our fiscal year ending December 31, 2003.



On February 6, 2004, shareholders holding a majority of the shares of our common stock voted to change the name of the Company to Acron Genomics Inc.  Such name change was effected by filing Articles of Amendment with the Secretary of State of Nevada.  No Proxies were solicited in connection with this shareholders vote.  A total of 5,430,000 shares out of a total of 10,115,000 shares issued and outstanding, were voted in favor of this action.  On March 19, 2004, the Company corrected a typographical error associated with the name change and the name of the Company became Acrongenomics Inc.



PART II

ITEM 5.

MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.



Our common stock, par value $0.001 per share, is quoted and traded on the Over-the-Counter/Bulletin Board under the symbol "AGNM". The following table lists, by calendar quarter, the volume of trading and the high and low sales prices of our common shares for each of the periods indicated:



2









|Period         | High  | Low  
|-------------- | ----- | -----
|2003:          |       |      
|Third Quarter* | $0.51 | $0.25
|Fourth Quarter | $1.01 | $0.35



*Commencing on July 15, 2003.



The above information was obtained from www.yahoo.com. Quotations commenced on the NASD-OTC-BB on July 15, 2003. These over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.



Rules 15g-1 through 15g-9 promulgated under the Securities Exchange Act of 1934, as amended, impose sales practice and disclosure requirements on NASD broker-dealers who make a market in "penny stocks". A penny stock generally includes any non-NASDAQ equity security that has a market price of less than $5.00 per share.  The price of our shares ranged from $0.25 (low) to $2.75 (high) during the period from July 15, 2003 to April 8, 2004.  The closing price of our shares on April 8, 2004 was $2.60.  Purchases and sales of our shares are generally facilitated by NASD broker-dealers who act as market makers for our shares.  The additional sales practice and disclosure requirements imposed upon broker-dealers may discourage broker-dealers from effecting transactions in our shares, which could severely limit the market liquidity of the shares and impede the sale of our shares in the secondary market.



Under the penny stock regulations, a broker-dealer selling penny stock to anyone other than an established customer or "accredited investor" (generally, an individual with net worth in excess of $1,000,000 or an annual income exceeding $200,000, or $300,000 together with his or her spouse) must make a special suitability determination for the purchaser and must receive the purchaser's written consent to the transaction prior to sale, unless the broker-dealer or the transaction is otherwise exempt.



In addition, the penny stock regulations require the broker-dealer to deliver, prior to any transaction involving a penny stock, a disclosure schedule prepared by the Commission relating to the penny stock market, unless the broker-dealer or the transaction is otherwise exempt.  A broker-dealer is also required to disclose commissions payable to the broker-dealer and the registered representative and current quotations for the securities.  Finally, a broker-dealer is required to send monthly statements disclosing recent price information with respect to the penny stock held in a customer's account and information with respect to the limited market in penny stocks.



Dividends



We have never paid dividends on our common shares.  There are no restrictions that may limit our ability to pay dividends currently or in the future.  We do not anticipate paying any dividends in the foreseeable future.



Shareholders



As of March 24, 2004 we had approximately 40 shareholders of record.

3









Recent Sales of Unregistered Securities



We did not complete any unregistered sales of our common stock during our fiscal year ended December 31, 2003, except as follows:



We completed an offering of 15,000 shares of our common stock at a price of $0.20 per share to a total of fifteen purchasers on March 15, 2002.  The total amount received from this offering was $3,000. We completed the offering pursuant to Regulation S of the Securities Act.  All sales were made in reliance of Category 3 of Rule 903 of Regulation S on the basis that:  (a) each sale was an offshore transaction; (b) no directed selling efforts were made by us in completing any sales; and (c) offering restrictions were implement.  These offering restrictions included endorsing all stock certificates representing the purchased shares with the legend required by Rule 905 of Regulation S.  Each purchaser was a person previously known to Mr. Jack Morgan, our sole executive officer and director, who satisfied the requirements of the exemption from the prospectus requirements of the British Columbia Securities Act for sales by private issuers. The private issuer exemption under the British Columbia Securities Act enables private issuers to sell to persons who do not require the benefit of a prospectus by virtue of their degree of sophistication, their financial resources or their relationship with the a director or officer of the issuer.  Each purchaser: (a) certified to us that purchaser is not a U.S. person as defined in Regulation S; (b) agreed to resell the purchased shares only in accordance with the provisions of Regulation S, pursuant to registration under the Act, or pursuant to an available exemption from registration; (c) agreed not to engage in hedging transactions with regard to the shares unless in compliance with the Act; and (d) agreed that we were required to refuse to register any transfer of the shares not in compliance with the provisions of Regulation S, pursuant to registration under the Act or pursuant to an available exemption from registration.  We did not engage in a distribution of this offering in Canada.  Each purchaser represented his intention to acquire the securities for investment only and not with a view toward distribution.  Each investor was given adequate access to sufficient information about us to make an informed investment decision.  None of the securities were sold through an underwriter and accordingly, there were no underwriting discounts or commissions involved.  No registration rights were granted to any of the purchasers.





ITEM 6.

MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.

PLAN OF OPERATIONS



Our plan of operations for the next twelve months is to complete the following objectives within the time period specified, subject to our obtaining financing for the development of our business plan and operations:



(1) To close on one or more of the target companies or operations that we have identified; and



(2) To raise sufficient capital in order to operate target company(ies)



Although it is anticipated that we will utilize our common stock as a means of acquiring these target companies, we do anticipate raising $2,000,000 in order to maintain sufficient working capital for ongoing operations.



We therefore anticipate that we will be spending approximately $2,000,000 over the next twelve-month period pursuing this plan of operations. Of these anticipated expenditures, we anticipate that $1,000,000 will be spent on our plan of operations in the next six months. Our cash position was $23,274 as of December 31, 2003.

4







Results Of Operations



We earned only $1,078 in revenues during the year ended December 31, 2003 and earned no revenues during the year ended December 31, 2002.  We do not anticipate earning revenues until such time as we close on an acquisition in accordance with our business plan and commence sales.  We are presently in the development stage and we can provide no assurance that we will be successful in completing any acquisitions or earning revenues from any acquisitions.



We incurred operating expenses in the amount of $22,654 for the year ended December 31, 2003, compared to operating expenses in the amount of $24,818 for the year ended December 31, 2002. Operating expenses incurred during the year ended December 31, 2003 included professional fees in the amount of $10,171, paid primarily for legal and auditing services. We anticipate that our professional expenses will increase in 2004 as more personnel are hired to implement our business plan.



We incurred a loss of $22,654 for the year ended December 31, 2003 and a loss of $24,818 for the year ended December 31, 2002.  Our net losses were attributable entirely to our operating expenses.



We anticipate continuing operating losses in the foreseeable future.  We base this expectation in part on the fact that we will incur substantial operating expenses in completing our stated plan of operations before we will have the opportunity to earn revenues.



Financial Condition and Liquidity



We had cash of $ 23,274 as of December 31, 2003, compared to cash of $43,128 as of December 31, 2002.  We had working capital of $21,109 as of December 31, 2003, compared to working capital of $42,685 as of December 31, 2002.



As discussed above under Plan of Operations, we anticipate that we will be spending approximately $2,000,000 over the next twelve-month period pursuing this plan of operations.  Of these anticipated expenditures, we anticipate that $1,000,000 will be spent on our plan of operations in the next six months.



We anticipate that our present cash reserves are sufficient for us to sustain our business operations for only the next two (2) months.  We anticipate that we will require additional financing in the amount of $2,000,000 in order to pursue our business plan.  We anticipate that if we pursue any additional financing, the financing would be an equity financing achieved through the sale of our common stock.  We do not have any arrangement in place for any debt or equity financing.  If we are successful in completing an equity financing, existing shareholders will experience dilution of their interest in our company.  In the event we are not successful in obtaining such financing when necessary, we may not be able to proceed with our business plan.



ITEM 7.

FINANCIAL STATEMENTS.

Index to Financial Statements:



1.

Auditors Report;



2.

Audited Financial Statements for the year ended December 31, 2003, including:



a.

Balance Sheets as at December 31, 2003 and 2002;



b.

Statements of Loss and Deficit for the years ended December 31, 2003 and 2002;



c.

Statements of Cash Flows for the years ended December 31, 2003 and 2002;



d.

Statements of Stockholders Equity for the years ended December 31, 2003 and 2002;



a.

Notes to Financial Statements.



5







































































ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)





FINANCIAL STATEMENTS





DECEMBER 31, 2003 AND 2002

(Stated in U.S. Dollars)











MORGAN & COMPANY

CHARTERED ACCOUNTANTS





AUDITORS' REPORT





To the Shareholders and Directors

Acrongenomics, Inc.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



We have audited the balance sheets of Acrongenomics, Inc. (formerly Cellway Ventures Inc.) (a development stage company) as at December 31, 2003 and 2002, and the statements of loss and deficit accumulated during the development stage, cash flows, and stockholders equity for the years ended December 31, 2003 and 2002, and for the period from August 17, 1999 (date of inception) to December 31, 2003.  These financial statements are the responsibility of the Company's management.  Our responsibility is to express an opinion on these financial statements based on our audits.



We conducted our audits in accordance with United States generally accepted auditing standards.  Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.  An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.  We believe that our audit provides a reasonable basis for our opinion.



In our opinion, these financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2003 and 2002, and the results of its operations and cash flows for the years ended December 31, 2003 and 2002, and for the period from August 17, 1999 (date of inception) to December 31, 2003 in accordance with United States generally accepted accounting principles.



The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  As discussed in Note 1(c) to the financial statements, the Company incurred a net loss of $56,891 since inception, has not attained profitable operations and is dependent upon obtaining adequate financing to fulfil its exploration activities.  These factors raise substantial doubt that the Company will be able to continue as a going concern.  Managements plans in regard to these matters are also discussed in Note 1(c).  These financial statements do not include any adjustments that might result from the outcome of this uncertainty.



Vancouver, B.C.

Morgan & Company



March 15, 2004

Chartered Accountants

F-1









ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



BALANCE SHEETS

(Stated in U.S. Dollars)







|                                                           | DECEMBER 31
|---------------------------------------------------------- | -----------
|                                                           |            
|                                                           |            
|ASSETS                                                     |            
|                                                           |            
|Current                                                    |            
|Cash                                                       | $          
|Prepaid expenses                                           |            
|                                                           |            
|                                                           | $          
|                                                           |            
|LIABILITIES                                                |            
|                                                           |            
|Current                                                    |            
|Accounts payable                                           | $          
|                                                           |            
|SHAREHOLDERS EQUITY                                       |            
|                                                           |            
|Share Capital                                              |            
|Authorized:                                                |            
|100,000,000 common shares, par value with $0.001 per share |            
|                                                           |            
|Issued and outstanding:                                    |            
|10,115,000 common shares at December 31, 2003 and 2002     |            
|                                                           |            
|Additional paid-in capital                                 |            
|                                                           |            
|Deficit Accumulated During The Development Stage           |            
|                                                           |            
|                                                           |            
|                                                           | $          







F-2







ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



STATEMENTS OF LOSS AND DEFICIT

(Stated in U.S. Dollars)







|                                                                    |             |             | INCEPTION
|------------------------------------------------------------------- | ----------- | ----------- | ---------
|                                                                    |             |             | AUGUST 17
|                                                                    | YEARS ENDED | 1999 TO    
|                                                                    | DECEMBER 31 | DECEMBER 31
|                                                                    | 2003        | 2002        | 2003     
|                                                                    |             |             |          
|Income                                                              |             |             |          
|Advertising                                                         | $           | 1,078       | $        
|                                                                    |             |             |          
|Expenses                                                            |             |             |          
|Domain registration                                                 |             | -           |          
|Transfer agent                                                      |             | 75          |          
|Consulting fees                                                     |             | 5,347       |          
|Professional fees                                                   |             | 10,171      |          
|Office and sundry                                                   |             | 7,061       |          
|Website development                                                 |             | -           |          
|                                                                    |             | 22,654      |          
|                                                                    |             |             |          
|Net Loss For The Year                                               |             | 21,576      |          
|                                                                    |             |             |          
|Deficit Accumulated During The Development Stage, Beginning Of Year |             | 35,315      |          
|                                                                    |             |             |          
|Deficit Accumulated During The Development Stage, End Of Year       | $           | 56,891      | $        
|                                                                    |             |             |          
|                                                                    |             |             |          
|Net Loss Per Share, Basic and diluted                               | $           | 0.01        | $        
|                                                                    |             |             |          
|                                                                    |             |             |          
|Weighted Average Number Of Shares Outstanding                       |             | 10,115,000  |          



F-3







ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



STATEMENTS OF CASH FLOWS

(Stated in U.S. Dollars)







|                                                                         |             |             | INCEPTION
|------------------------------------------------------------------------ | ----------- | ----------- | ---------
|                                                                         |             |             | AUGUST 17
|                                                                         | YEARS ENDED | 1999 TO    
|                                                                         | DECEMBER 31 | DECEMBER 31
|                                                                         | 2003        | 2002        | 2003     
|                                                                         |             |             |          
|Cash Flows From Operating Activity                                       |             |             |          
|Net loss for the year                                                    | $           | (21,576)    | $        
|                                                                         |             |             |          
|Adjustments To Reconcile Net Loss To Net Cash Used By Operating Activity |             |             |          
|Change in accounts payable                                               |             | 1,832       |          
|Change in prepaid expenses                                               |             | (110)       |          
|                                                                         |             | (19,854)    |          
|                                                                         |             |             |          
|Cash Flows From Financing Activity                                       |             |             |          
|Share capital                                                            |             | -           |          
|                                                                         |             |             |          
|Increase (Decrease) In Cash                                              |             | (19,854)    |          
|                                                                         |             |             |          
|Cash, Beginning Of Year                                                  |             | 43,128      |          
|                                                                         |             |             |          
|Cash, End Of Year                                                        | $           | 23,274      | $        



F-4







ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



STATEMENT OF STOCKHOLDERS EQUITY



DECEMBER 31, 2003

(Stated in U.S. Dollars)







|                                 | COMMON STOCK |        |           
|-------------------------------- | ------------ | ------ | ----------
|                                 |              |        | ADDITIONAL
|                                 |              |        | PAID-IN   
|                                 | SHARES       | AMOUNT | CAPITAL   
|                                 |              |        |           
|Shares issued for cash at $0.001 | 5,000,000    | $      | 5,000     
|Shares issued for cash at $0.01  | 5,000,000    |        | 5,000     
|Net loss for the period          | -            |        | -         
|                                 |              |        |           
|Balance, December 31, 1999       | 10,000,000   |        | 10,000    
|                                 |              |        |           
|Shares issued for cash at $0.20  | 100,000      |        | 100       
|Net loss for the year            | -            |        | -         
|                                 |              |        |           
|Balance, December 31, 2000       | 10,100,000   |        | 10,100    
|                                 |              |        |           
|Net loss for the year            | -            |        | -         
|                                 |              |        |           
|Balance, December 31, 2001       | 10,100,000   |        | 10,100    
|                                 |              |        |           
|Shares issued for cash at $0.20  | 15,000       |        | 15        
|Net loss for the year            | -            |        | -         
|                                 |              |        |           
|Balance, December 31, 2002       | 10,115,000   |        | 10,115    
|                                 |              |        |           
|Net loss for the year            | -            |        | -         
|                                 |              |        |           
|Balance, December 31, 2003       | 10,115,000   | $      | 10,115    



F-5







ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



NOTES TO FINANCIAL STATEMENTS



DECEMBER 31, 2003 AND 2002

(Stated in U.S. Dollars)







1.

NATURE OF OPERATIONS



Organization



The Company was incorporated in the State of Nevada, U.S.A. on August 17, 1999.



Development Stage Activities



The Company plans to launch a free information Website to assist and attract people wanting information on immigration to Canada. The Company plans to use the Website to earn income from companies who are prepared to pay to have Web advertising in the form of a button or banners on the Website selling their products or services. The Company plans to solicit advertisers who are targeting sales of their products and services at people using the Companys website.



The Company is in the development stage, therefore, recovery of its assets is dependent upon future events, the outcome of which is indeterminable.  In addition, successful completion of the Companys development program and its transition, ultimately to the attainment of profitable operations is dependent upon obtaining adequate financing to fulfil its development activities and achieve a level of sales adequate to support its cost structure.



c)

Going Concern



Since inception, the Company has suffered recurring losses and net cash outflows from operations.  The Company expects to continue to incur substantial losses to complete the development of its business.  Since its inception, the Company has funded operations through common stock issuances in order to meet its strategic objectives.  Management believes that sufficient funding will be available to meet its business objectives, including anticipated cash needs for working capital, and is currently evaluating several financing options.  However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of and, if successful, to commence the sale of its products under development.  As a result of the foregoing, there exists substantial doubt about the Companys ability to continue as a going concern.  These financial statements do not include any adjustments that might result from the outcome of this uncertainty.



F-6





ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



NOTES TO FINANCIAL STATEMENTS



DECEMBER 31, 2003 AND 2002

(Stated in U.S. Dollars)







2.

SIGNIFICANT ACCOUNTING POLICIES



The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States.  Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements for a period necessarily involves the use of estimates which have been made using careful judgement.



The financial statements have, in managements opinion, been properly prepared within reasonable limits of materiality and within the framework of the significant accounting policies summarized below:



Development Stage Company



The Company is a developed stage company as defined in the Statements of Financial Accounting Standards No. 7. The Company is devoting substantially all of its present efforts to establish a new business and none of its planned principal operations have commenced. All losses accumulated since inception have been considered as part of the Companys development stage activities.



Use of Estimates



The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses for the reporting period.  Actual results could differ from these estimates.



Software Development Costs



Software development costs prior to the application development stage are expensed as incurred.  Once the application stage is reached, costs of design, configuration, coding, installation and testing of the Companys website will be capitalized.  Upon implementation of the website, the asset will be amortized to expense over its estimated useful life of three years using the straight line method.  Ongoing website post-implementation costs of operation, including training and application maintenance, will be charged to expense as incurred.

F-7





ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



NOTES TO FINANCIAL STATEMENTS



DECEMBER 31, 2003 AND 2002

(Stated in U.S. Dollars)







2.

SIGNIFICANT ACCOUNTING POLICIES (Continued)



d)

Income Taxes



The Company has adopted Statement of Financial Accounting Standards No. 109  Accounting for Income Taxes (SFAS 109).  This standard requires the use of an asset and liability approach for financial accounting and reporting on income taxes.  If it is more likely than not that some portion or all if a deferred tax asset will not be realized, a valuation allowance is recognized.



e)

Financial Instruments



The Companys financial instruments consist of cash and accounts payable.



Unless otherwise noted, it is managements opinion that this Company is not exposed to significant interest or credit risks arising from these financial instruments.  The fair value of these financial instruments approximate their carrying values, unless otherwise noted.



f)

Foreign Currency Translation



The Companys functional currency is the U.S. dollar.  Transactions in foreign currencies are converted to U.S. dollars at the rate of exchange prevailing at the time of the transactions.  Exchange gains and losses arising from the remeasurement of foreign currency-denominated assets and liabilities are included in income in the period in which they occur.



g)

Revenue Recognition



The Company earns revenue by selling advertising space on its website.  Revenue is recognized over the term of the advertising contract.



h)

Basic and Diluted Loss Per Share



In accordance with SFAS No. 128  Earnings Per Share, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding.  Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.  At December 31, 2003, the Company has no stock equivalents that were anti-dilutive and excluded in the earnings per share computation.

F-8





ACRONGENOMICS, INC.

(Formerly Cellway Ventures Inc.)

(A Development Stage Company)



NOTES TO FINANCIAL STATEMENTS



DECEMBER 31, 2003 AND 2002

(Stated in U.S. Dollars)







3.

SUBSEQUENT EVENT



SUBSEQUENT TO DECEMBER 31, 2003, THE COMPANY HAS SIGNED A LETTER OF INTENT WITH A GROUP OF EUROPEAN SCIENTISTS TO PURCHASE THE PATENTS AND ALL ASSOCIATED RIGHTS TO THEIR HIGHLY PREDICTIVE, METASTIC CANCER MOLECULAR DIAGNOSTIC TEST PRODUCTS IN CONSIDERATION OF THE ISSUANCE BY THE COMPANY OF 4,000,000 COMMON SHARES.

F-9







ITEM 8.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

Not applicable.



ITEM 8A.

CONTROLS AND PROCEDURES.



We maintaindisclosure controls and proceduresthat are designed to ensure that information required to be disclosed inour Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.



Within the last 90 days,  we carried out anevaluation, undertaken by our sole officer and director, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-14.  Based upon the foregoing, our Chief Executive Officer /Chief Financial Officerconcluded thatourdisclosure controls and procedures are effective.



There were no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation, including any significant deficiencies or material weaknesses of internal controls that would require corrective action.



PART III

ITEM 9.

DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT.

Our executive officers and directors and their respective ages as of April 5, 2004 are as follows:



Directors:

|Name of Director      | Age
|--------------------- | ---
|W. Scott Lawler, Esq. | 42 



Officers:

|Name of Officer | Age | Office Held                       
|--------------- | --- | ----------------------------------
|W. Scott Lawler | 42  | President, Secretary and Treasurer



Set forth below is a brief description of the background and business experience of Mr. Lawler, our sole director and executive officer:



W. Scott Lawlerhas been our sole officer and director since February 2, 2004.  Mr. Lawler is an attorney and is admitted in the State of California. Mr. Lawler received a Bachelor's Degree in business management in 1984 from Brigham Young University and his Juris Doctorate degree from U.S.C. Law Center in 1988. Mr. Lawler was admitted to the California State Bar in 1988 and the Utah State Bar in 1995. Mr. Lawler has been the principal of Lawler & Associates, specializing in corporate and securities matters, since 1995. Mr. Lawler has been the President and sole shareholder of International Securities Group, Inc., a private consulting company since its inception on May 23, 2000. Mr. Lawler also currently serves as General Counsel and a member of the Board of Directors of FACT Corporation, a public company, and certain of its subsidiaries. From November 1, 1999 to August 7, 2001, Mr. Lawler served as the President of FACT Corporation.

6





Compliance With Section 16(A) Of The Securities Exchange Act



Section 16(a) of the Exchange Act requires the Company's executive officers and directors, and persons who beneficially own more than ten percent of the Company's equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission. Officers, directors and greater than ten percent shareholders are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms they file. Based on its review of the copies of such forms received by it, the Company believes that during the fiscal year ended December 31, 2003 all such filing requirements applicable to its officers and directors were complied with.



Board and Committees



The members of our Board of Directors are elected annually by our shareholders and hold office until the next annual shareholders meeting or until his successor is duly elected and qualified.  During 2003, the Board of Directors consisted of only one (1) member and therefore no formal meetings of the Board of Directors were held. Our Board of Directors acted during 2003 through written consents of the sole member of the Board of Directors.



The Board of Directors does not at this time have an Audit Committee. The Board of Directors performs the same functions as an audit committee. Since there is only one (1) member of the Board of Directors, it is not feasible at this time to have an audit committee.



Code of Ethics



As of the date of the filing of this report, the Company has not adopted a code of ethics that applies to its principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions.  The Company anticipates that it will prepare and adopt such a code of ethics during the second quarter of fiscal year 2004.  Upon completion and adoption, the Company intends to will a copy of its code of ethics with the Securities and Exchange Commission as an exhibit to its quarterly report for the period ended March 30, 2004 and will post it on the Companys website, once such website is established.



ITEM 10.

EXECUTIVE COMPENSATION.



The following table sets forth certain compensation information as to Mr. Jack Morgan, our sole officer and director for the past three fiscal years. No other compensation was paid to Mr. Morgan other than the compensation set forth below.





Summary Compensation Table





|                         |                                                 |                  | ANNUAL COMPENSATION | LONG TERM COMPENSATION
|------------------------ | ----------------------------------------------- | ---------------- | ------------------- | ----------------------
|Name                     | Title                                           | Year             | Salary              | Bonus                 
|Restricted Stock Awarded | Options/ SARs * (#)                             | LTIP payouts ($)
|Jack Morgan              | Director and President, Secretary and Treasurer | 2003
2002
2001   | $0
$0
$0            | 0
0
0                 







7





Stock Option Grants



We did not grant any stock options to the directors or executive officers during our most recent fiscal year ended December 31, 2003.  We have also not granted any stock options to the directors or executive officers since December 31, 2003.



Exercises Of Stock Options And Year-End Option Values



No stock options were exercised by our officers, directors or employees during the fiscal year ended December 31, 2003.  No stock options have been executed since December 31, 2003.



Outstanding Stock Options



We do not have any stock options outstanding.



Management Agreement



We presently are not a party to any management or other compensation agreement with Mr. W. Scott Lawler. Mr. Lawler receives $3,000 per month for serving as the Companys sole officer and director.  To date, he has been paid $3,000 and is owed $3,000 for such services.  Mr. Lawler also provides legal services to our company and is compensated for such services at the rate of $275 per hour. Mr. Lawler commenced providing such services to our company on or about February 4, 2004. Since that time, Mr. Lawler has been paid a total of $9,151.72 for legal services.



ITEM 11.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.

The following table sets forth certain information concerning the number of shares of our common stock owned beneficially as of March 24, 2003 by: (i) each person (including any group) known to us to own more than five percent (5%) of any class of our voting securities, (ii) each of our directors, and (iii) officers and directors as a group. Unless otherwise indicated, the shareholders listed possess sole voting and investment power with respect to the shares shown.



|Title of class | Name and address
of beneficial owner                                                                       | Number of Shares of Common Stock | Percentage of Common Stock(1)
|-------------- | ---------------------------------------------------------------------------------------------------------- | -------------------------------- | -----------------------------
|Common Stock   | W. Scott Lawler
President, Secretary and Treasurer/Director
1530 9th Avenue, S.E.
Calgary, Alberta T2G 0T7 | 5,000,000 Shares                 | 49.5%                        
|Common Stock   | All Officers and Directors as a Group (1 person)                                                           | 5,000,000 Shares                 | 49.5%                        



(1)

Based on 10,115,000 shares of our common stock issued and outstanding as of March 24, 2004.



8





Except as otherwise noted, it is believed that all persons have full voting and investment power with respect to the shares indicated. Under the rules of the Securities and Exchange Commission, a person (or group of persons) is deemed to be a beneficial owner of a security if he or she, directly or indirectly, has or shares the power to vote or to direct the voting of such security, or the power to dispose of or to direct the disposition of such security. Accordingly, more than one person may be deemed to be a beneficial owner of the same security. A person is also deemed to be a beneficial owner of any security, which that person has the right to acquire within 60 days, such as options or warrants to purchase the Common Stock of the Company.



Change In Control



We are not aware of any arrangement that might result in a change in control of our company in the future.

ITEM 12.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.



Except as described above under ITEM 10  EXECUTIVE COMPENSATION  Management Agreements, none of the following persons has any direct or indirect material interest in any transaction to which we were or are a party during the past two years, or in any proposed transaction to which the Company proposes to be a party:



(A)

any director or officer;



(B)

any proposed nominee for election as a director;



(C)

any person who beneficially owns, directly or indirectly, shares carrying more than 5% of the voting rights attached to our common stock; or



(D)

any relative or spouse of any of the foregoing persons, or any relative of such spouse, who has the same house as such person or who is a director or officer of any parent or subsidiary.



ITEM 13.

EXHIBITS AND REPORTS ON FORM 8-K.



(a)

Exhibits.





|Exhibit Number | Description of Exhibit                
|-------------- | --------------------------------------
|3.1            | Articles of Incorporation (1)         
|3.2            | Bylaws, as amended (1)                
|4.1            | Share Certificate (1)                 
|31             | Rule 13a-14(a)/15d-14(a) Certification
|32             | Section 1350 Certification            





(1)

Previously filed with the Securities and Exchange Commission as an exhibit to the Registrants Form 10-SB originally filed May 24, 2002, as amended.



9





(a)

Reports on Form 8-K.



No reports on Form 8-K were filed during the last quarter of our fiscal year ended December 31, 2003.



On February 2, 2004, we filed a Form 8-K to report that Mr. Lawler replaced Mr. Morgan as our sole officer and director and became our largest shareholder.



ITEM 14.

PRINCIPAL AUDITORS FEES.



Audit Fees



The aggregate fees billed for each of the last two fiscal years for professional services rendered by Morgan & Company for the audit of our annual financial statements and review of financial statements included in our Form 10-QSB quarterly reports and services normally provided by Morgan & Company in connection with statutory and regulatory filings or engagements were $3,500 for the fiscal year ended 2003 and $3,500 for the fiscal year ended 2002.



Audit-Related Fees



There were no fees for other audit related services for the fiscal years ended 2003 and 2002.



Tax Fees



There were no fees for tax related services for the fiscal years ended 2003 and 2002.





All Other Fees



There were no other aggregate fees billed in either of the last two fiscal years for products and services provided by Morgan & Company, other than the services reported above.



10





SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.





ACDRONGENOMICS INC.





By:_/s/ W. SCOTT LAWLER_________________

W. Scott Lawler, President and Chief Executive Officer

Director

Date:

April 14, 2004





In accordance with the Securities Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.







By:_/s/ W. SCOTT LAWLER_________________

W. Scott Lawler, President, Secretary and Treasurer

Chief Executive Officer and Chief Financial Officer

(Principal Executive Officer and Principal Accounting Officer)

Director

Date:

April 14, 2004





#